Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

ENROLLING BY INVITATION

NCT07154238

Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.

Sponsor: Novo Nordisk A/S

View on ClinicalTrials.gov

Summary

The purpose of this study is to collect information for scientific research and to better understand the experiences of participants managing their weight. The study aims to collect valid responses through online interviews from participants. This study is a survey-based study without collection of laboratory data. Duration of the study will be about 14 months.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

2546

Start Date

2025-09-26

Completion Date

2026-09-30

Last Updated

2025-11-25

Healthy Volunteers

Conditions

Obesity

Interventions

OTHER

No treatment given

Inclusion Criteria: * For an eligible participant (individuals initiated on injectable semaglutide for weight management), all inclusion criteria must be answered "yes". 1. Electronically provided consent obtained before any study-related activities can be completed. 2. Age above or equal to 18 years at the time of providing informed consent. 3. Reside in a participating country: Australia, Germany, United Arab Emirates (UAE) and Spain. 4. Have been prescribed and initiated injectable semaglutide for weight management prior to study screening. * For an eligible participant (HCPs), all inclusion criteria must be answered "yes". 1. Electronically provided consent obtained before any study-related activities can be completed. 2. Practice in a participating country: Australia, Germany, UAE, and Spain. 3. See at least 150 patients for any condition per month; priority given to those who treat at least 200 patients for any condition per month. 4. Treat at least 10 adult patients per month for weight management. 5. Prescribe anti-obesity medications (AOMs) to their patients they personally treat for weight management/obesity care; priority given to those who treat at least 10% of the patients they personally treat for weight management/obesity care with anti-obesity medications (AOMs). 6. Prescribe injectable semaglutide for weight management. 7. Be a specialty of interest (varies by country); mix of primary care, specialists such as Endocrinologists, Diabetologists, Nutrition Specialists, Obesity Specialists and others. Exclusion Criteria: * For an eligible participant (individuals initiated on injectable semaglutide for weight management), all exclusion criteria must be answered "no". 1. Unwillingness or language barriers precluding adequate understanding or cooperation. 2. Is currently or planning to become pregnant in next six months. 3. Is taking injectable semaglutide for Type 2 diabetes management only. * For an eligible participant (HCPs), all exclusion criteria must be answered "no". 1. Prior participation in this study. Participation is defined as having given informed consent and submitting responses to an interview. 2. Unwillingness or language barriers precluding adequate understanding or cooperation. 3. Only treats patients under 18 years of age.

Locations (1)

Novo Nordisk Investigational Site

Bad Oeynhausen, Germany